Journal
VACCINE
Volume 27, Issue 47, Pages 6512-6521Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.08.053
Keywords
Influenza; Immunization; Heterosubtypic immunity; DNA vaccine; Prime-boost; Recombinant adenovirus; Cold-adapted; H5N1; Pandemic; Vaccine; Ferret; Mice; Intranasal; Systemic; Intramuscular
Categories
Funding
- FDA
- National Vaccine Program Office
- Office of Public Health Emergency Medical Countermeasures
- CBER Pandemic Influenza Initiative
Ask authors/readers for more resources
Immunization against conserved virus components induces broad, heterosubtypic protection against diverse influenza A viruses, providing a strategy for controlling unexpected outbreaks or pandemics until strain-matched vaccines become available. This study characterized immunization to nucleoprotein (NP) and matrix 2 (M2) by DNA priming followed by parenteral or mucosal boosting in mice and ferrets. DNA vaccination followed by boosting with antigen-matched recombinant adenovirus (rAd) or cold-adapted (ca) influenza virus provided robust protection against virulent H1N1 and H5N1 challenges. Compared to other boosts, mucosal rAd induced stronger IgA responses, more virus-specific activated T-cells in the lung, and better protection against morbidity following challenge even eight months post-boost. In ferrets, both mucosal and parenteral rAd boosting protected from lethal H5N1 challenge. These findings demonstrate potent protection by vaccination highly focused on conserved antigens and identify immune response measures in mice that differed among vaccinations and correlated with outcome. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available